Abemaciclib: 15 agencies, 2018–2026
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
Assessment has run over 7.5 years, from 12 Dec 2018 at HAS (France) to 16 Jun 2026 at PHARMAC (New Zealand).
SMC (Scotland) changed its position: restricted on 13 May 2019, recommended by 12 Dec 2022.
No assessment is on file from CIPM (Spain), which is among the eight highest-volume agencies here.
The file is active: 13 of 47 records date from 2023 or later.
7 distinct indication wordings are recorded for abemaciclib by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
6 of these 47 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess abemaciclib, on 12 Dec 2018; PHARMAC (New Zealand) did not open a file until 12 Feb 2026 — a wide spread of 7.2 years between the earliest and latest system to look at it.
The record arrives in waves: 8 separate years each carry two or more decisions, spread across 9 years in total.
12 of the 15 agencies here assessed abemaciclib more than once, G-BA (Germany) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
abemaciclib has been through 15 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for abemaciclib reads 25 recommended, 7 not recommended, 7 restricted and 4 no benefit, with 4 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| PHARMAC (New Zealand) | 12 Feb 2026 | Metastatic breast cancer, HR positive, HER2 negative | PTAC advice: Cost Neutral | source |
| CONITEC (Brazil) | 3 Nov 2025 | Tratamento de câncer de mama precoce, receptor hormonal positivo, receptor do fator de crescimento epidérmico humano 2 (… | incorporated into SUS | source |
| DMC (Denmark) | 3 Sep 2025 | Patienter med tidlig, høj-risiko, lymfeknudepositiv ER+/HER2 brystkræft | Anbefalet | source |
| ZIN (Netherlands) | 11 Apr 2025 | Advies - niet vergoeden abemaciclib (Verzenios®) voor de behandeling van borstkanker (herbeoordeling) | not reimbursed (sluis) | source |
| HAS (France) | 26 Mar 2025 | Re-assessment of SMR and ASMR | SMR substantial · ASMR III | source |
42 further decisions for abemaciclib, across 14 agencies, are not shown here. They include the most recent record on file, 16 Jun 2026 from PHARMAC (New Zealand); its outcome is in the subscriber dataset. They link to 31 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 47 decisions for abemaciclib from 15 agencies, 2018 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.